Newsroom

LONDON--(BUSINESS WIRE)--  15-January-2026 Issue: Clydesdale Bank plc CB Series 3 XS2443513440 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 22-October-2025 Date To: 22-January-2026 Record Date: 21-January-2026 Value Date: 22-January-2026 Benchmark Rate: 3.92536% Margin: 0.28% Total Rate: 4.20536% Floor: 0% Number of Days: 92 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Denomination: G...

WICHITA, Kansas--(BUSINESS WIRE)--Le Cessna Citation M2 Gen2 équipé des commandes Autothrottles de Garmin est récemment entré en service. Certifiée par la Federal Aviation Administration en octobre 2025, l'intégration des commandes Autothrottles de Garmin sur le Citation M2 Gen2 renforce davantage les capacités du jet d'entrée de gamme le plus livré et offre aux pilotes plus de contrôle et de précision. Le Cessna Citation M2 Gen2 est conçu et fabriqué par Textron Aviation Inc., une société de T...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new real-time clinical intelligence service for Salesforce’s Agentforce Life Sciences. These services will power new and existing agentic solutions for life sciences customers, including a data integration that will bring Viz.ai’s real-time data, triggers, and clinical intelligence layer from across a network of nearly 2,000 hospitals covering 230...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Mission Produce, Inc. (NASDAQ: AVO) and Calavo Growers, Inc. is fair to Mission shareholders. Upon completion of the proposed transaction, Mission shareholders are expected to own approximately 80.3% of the combined company. Halper Sadeh encourages Mission shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212)...

WICHITA, Kan.--(BUSINESS WIRE)--De Cessna Citation M2 Gen2 met Garmin Autothrottles is onlangs in gebruik genomen. Het Autothrottle-systeem van Garmin, dat in oktober 2025 werd gecertificeerd door de Federal Aviation Administration, wordt geïntegreerd in de Citation M2 Gen2. Hierdoor heeft het meest geleverde lichte jetvliegtuig nog meer mogelijkheden om piloten meer controle en precisie te bieden. De Cessna Citation M2 Gen2 is ontworpen en geproduceerd door Textron Aviation Inc., een bedrijf v...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Memphre Investments GP, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be na...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best will host a complimentary webinar, titled, “The Responsible Use of Data in the Insurance Industry,” sponsored by LexisNexis Risk Solutions, on Wednesday, Jan. 28, 2026, at 2:00 p.m.( EST). Register today. In this webinar, a panel of insurance experts will explore how accurate, ethical and transparent data practices can strengthen underwriting, protect consumers and support fair, innovative insurance markets. This panel brings together experts in consumer...

WICHITA, Kansas--(BUSINESS WIRE)--Recentemente è entrato in servizio il Cessna Citation M2 Gen2 dotato del sistema di automanetta Garmin, certificato dalla Federal Aviation Administration (FAA) nell’ottobre 2025. L’integrazione del sistema di manetta automatica Garmin potenzia ulteriormente le capacità del jet light-entry più diffuso sul mercato, garantendo ai piloti un controllo e una precisione superiori. Il Cessna Citation M2 Gen è progettato e fabbricato da Textron Aviation Inc., un’impresa...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--A Agenus Inc. (Nasdaq: AGEN), líder em inovação em imunooncologia, anunciou hoje a conclusão de sua colaboração estratégica previamente divulgada com a Zydus Lifesciences Ltd. O acordo foi estruturado para acelerar o desenvolvimento global e a potencial comercialização do programa de imunoterapia combinada botensilimabe e balstilimabe (BOT+BAL) da Agenus. A colaboração fornece à Agenus capital estratégico e capacidade comprometida de longo prazo para a...

麻薩諸塞州萊辛頓--(BUSINESS WIRE)--(美國商業資訊)-- 免疫腫瘤學創新領域的領導者Agenus Inc. (Nasdaq: AGEN)今日宣布，已達成此前公布的與Zydus Lifesciences Ltd.的策略性合作。該協議旨在加快Agenus旗下botensilimab與balstilimab (BOT+BAL)免疫組合療法的全球研發和潛在商業化進程。 此次合作將為Agenus提供策略資金支援，以及美國本土長期專屬的生物製劑生產產能，為BOT+BAL的臨床研發、授權早期准入通路及商業化供應籌備提供保障。 在此次合作中，Agenus授予Zydus在印度和斯里蘭卡開發並商業化BOT和BAL的獨家權利，Agenus有資格從這些地區的淨銷售額中獲得權利金。 該合作最初於2025年6月3日宣布，核心財務條款包括： 預付款項：Zydus向Agenus支付7500萬美元現金，用於收購其位於加州愛莫利維爾和柏克萊的生物製劑生產設施 股權投資：Zydus收購Agenus (AGEN)價值1600萬美元的普通股（約210萬股，價格為每股7.50美元） 或有里程碑給付：若BOT+B...